LAWRENCE, Mass., Nov. 11, 2014 /PRNewswire/ -- NxStage® Medical,
Inc. (Nasdaq: NXTM) today announced that a new study conducted
by the Chronic Disease Research Group (CDRG) will be presented
orally and in a poster session at the American Society of
Nephrology's Kidney Week 2014, November 11 -
16 in Philadelphia,
Pennsylvania by Eric
Weinhandl, MS, PhD candidate, and epidemiologist at the
CDRG. The results of the first matched cohort study of its kind
show frequent home hemodialysis (HHD) patients have a 16% lower
risk of death, 8% lower risk of hospitalization, and 38% lower risk
of therapy attrition than peritoneal dialysis (PD) patients.
Using a 33-factor algorithm to match 4,460 frequent HHD patients
with 4,460 PD patients, the results of the study showed that there
was 13% lower risk of cardiovascular-related death and 20% lower
risk of infection-related death with HHD therapy.
Additionally, frequent HHD patients were 16% and 11% less likely to
be hospitalized for cardiovascular or infection-related diagnoses,
respectively.
"This study provides evidence that HHD is not only a viable
alternative to PD, but may be a better alternative for some
patients electing to perform home dialysis," said Weinhandl.
"Moreover, the study challenges the commonly held conception that
therapy attrition is higher with HHD than with PD."
In addition to CDRG findings, the FREEDOM Study, a research
project funded by NxStage, showed frequent home hemodialysis
treatment for ESRD patients is associated with a more positive and
sustained impact on quality of life than patients' prior therapies.
Together, these findings show that improved survival, better
hospitalization rate, and longer therapy retention on HHD therapy
may translate to a patient's perception of their overall quality of
life and general well-being.
"Our patients constantly tell us that home hemodialysis with the
NxStage System One has significantly changed their lives for the
better," said NxStage President, Joseph
Turk. "These findings present a compelling reason to further
strengthen HHD programs and expand patient access to this life
changing therapy."
Published abstracts and program details are available on the ASN
Kidney Week website.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared for
home use by the FDA. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow™ SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid. Unlike conventional hemodialysis
systems, the System One requires no special infrastructure to
operate. Under the guidance of their physician, patients can use
the NxStage System One, with their trained partners, where, how and
when it best meets their needs, at home or on vacation.
http://www.nxstage.com/.
About NxStage Medical,
Inc.
NxStage is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please
visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and
Exchange Commission, including the Quarterly Report on Form 10-Q
for the quarter ended September 30, 2014. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical, Inc.